In Russia, the health needs of an ageing population and an increasing demand for generic drugs is changing the face of the pharmaceutical industry. Today, drug imports account for nearly 60 percent of the total Russian pharmaceutical market, which prompted the government to establish so-called pharmaceutical clusters to promote local production and reduce dependence on imported healthcare products.
Yaroslavl, a city 250 kilometres north-east of Moscow, constitutes one of these pharmaceutical clusters established by the Russian Government. R-Pharm’s new state-of-the-art fill-finish manufacturing facility will be placed in Yaroslavl and will make the company one of the leading manufacturers and distributors of pharmaceuticals to the healthcare sector in Russia.
The R-Pharm facility will produce prescription drugs for the treatment of socially significant diseases, including cancers, haematological illnesses, arthritis, viral hepatitis, HIV and severe bacterial and fungal infections. Protected by patents, the drugs will be produced under license from foreign pharmaceutical companies.
First-class international design
NNE Pharmaplan is in charge of consulting, engineering and supervision services for the Yaroslavl plant, including conceptual, basic and detailed designs. The facility will comply with GMP (Good Manufacturing Practice) requirements. All production processes with harmful substances will be carried out using clean, contained equipment and areas, which are the first of its kind in Russia.
Our reputation as a global company with a strong local presence helped secure the contract, as well as our ability to deliver high-quality projects within a short timeframe. NNE Pharmaplan in Russia is responsible for the project design, with the support of colleagues from Denmark, Sweden, Finland and Germany.
The new R-Pharm facility is scheduled to start production in 2012.
Download the case story in PDF